AMGEN @ ASCO 2017

Amgen announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017.

Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease. XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO®

First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec)and a Checkpoint Inhibitor to be Presented

Key Trial Readouts

XGEVA® **denosumab**	Results from the Phase 3 '482 study, evaluating the efficacy and safety of denosumab versus zoledronic acid for the prevention of fractures and other bone complications in patients with newly diagnosed multiple myeloma. This abstract was also selected for inclusion in the Best of ASCO® educational program, designed to increase global access to cutting-edge science. Current treatment options for bone complications are limited to bisphosphonates, which are associated with renal toxicity. • Impact of Denosumab (DMB) Compared With Zoledronic Acid (ZA) on Renal Function in the Treatment of Myeloma Bone Disease (Abstract 8005)
Imlygic® (talimogene laherparepvec)	• Primary Results From a Randomized (1:1), Open-Label Phase 2 Study of Talimogene Laherparepvec (T) and Ipilimumab (I) Versus I Alone in Unresected Stage IIIB- IV Melanoma Abstract 9509 • Humanistic Burden of Disease in Earlier Stage Metastatic (Stage IIIB/C-IVM1A) Versus Late Stage Metastatic (IVM1B/C) Melanoma Patients in a Real World Setting in the US Abstract 9561
Blincyto® **blinatumomab**	• Blinatumomab Use in Pediatric Patients (Pts) With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (R/R ALL) From an Open-label, Multicenter, Expanded Access Study Abstract 10530 • Exposure-adjusted Adverse Events (AEs) Comparing Blinatumomab to Standard of Care (SOC) Chemotherapy in Patients (Pts) With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (R/R ALL) From a Randomized Phase III Study Abstract 7032
Kryopolis **Carfilzomib**	Data at ASCO include: • Rates of Peripheral Neuropathy (PN) in Patients (Pts) With Relapsed and Refractory Multiple Myeloma (RRMM) Treated With Carfilzomib vs Comparators in Pivotal Phase 3 Trials Abstract 8041
Panitumumab	Presentations featuring Vectibix® (panitumumab) data will include: • Profiling Circulating Tumor DNA (ctDNA) Mutations After Panitumumab Treatment in Patients With Refractory Metastatic Colorectal Cancer (mCRC) From the Phase III ASPECCT Study Abstract 3523 • Early Tumor Shrinkage (ETS) and Depth of Response (DpR) in Wild-Type (WT) RAS Tumors from the Phase III Trial of Panitumumab (Pmab) Plus Best Supportive Care (BSC) Versus BSC in Chemorefractory Metastatic Colorectal Cancer (mCRC) Abstract 3561 • Clinical Outcomes and Emergent Circulating Tumor (Ct) DNA RAS Mutations and Allele Fraction for Patients With Metastatic Colorectal Cancer (mCRC) Treated With Panitumumab from the ASPECCT Study Abstract 3584
ABP215	• **Clinical Comparison of ABP 215 and Bevacizumab in Patients With NSCLC: PK Results and Justification for Extrapolation Across Bevacizumab Indications** Abstract 9050

CORPORATE COMMUNICATIONS

"At Amgen, we are committed to translating science into innovative and effective treatments for cancer patients across the disease continuum," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The data that will be presented at this year's ASCO meeting highlight the potential of our marketed products in new patient populations and in combination with other therapies."